Avenue Therapeutics, Inc. (ATXI)
NASDAQ: ATXI · IEX Real-Time Price · USD
0.130
-0.003 (-2.26%)
At close: Apr 19, 2024, 4:00 PM
0.135
+0.005 (3.85%)
After-hours: Apr 19, 2024, 6:37 PM EDT
Company Description
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases.
Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.
The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.
Avenue Therapeutics, Inc.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jun 27, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Dr. Alexandra MacLean M.D. |
Contact Details
Address: 1111 Kane Concourse, Suite 301 Bay Harbor Islands, Florida 33154 United States | |
| Phone | 781-652-4500 |
| Website | avenuetx.com |
Stock Details
| Ticker Symbol | ATXI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001644963 |
| CUSIP Number | 05360L205 |
| ISIN Number | US05360L3042 |
| Employer ID | 47-4113275 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alexandra MacLean M.D. | Chief Executive Officer and Director |
| David Jin | Interim Chief Financial Officer, Chief Operating Officer and Corporate Secretary |
| Dr. Lindsay Allan Rosenwald | Executive Director |
| Dr. Xiaoqin Lu M.D. | Consultant |
| Dr. Scott A. Reines M.D., Ph.D. | Interim Chief Medical Officer |
| Srinivas Subramanian | Executive Vice President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 29, 2024 | 8-K | Current Report |
| Mar 18, 2024 | DEF 14C | Filing |
| Mar 18, 2024 | 10-K | Annual Report |
| Mar 18, 2024 | 8-K | Current Report |
| Mar 15, 2024 | 8-K | Current Report |
| Mar 8, 2024 | PRE 14C | Filing |
| Mar 8, 2024 | 8-K | Current Report |
| Feb 23, 2024 | 8-K | Current Report |
| Feb 2, 2024 | 424B3 | Prospectus |